Longitudinal Transcription Profiling of Bladder Cancers Dictate the Response to BCG Treatment and Disease Progression
International Journal of Molecular Sciences · 21.12.2023 · 25 (1) · 144
DOI: 10.3390/ijms25010144 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 21.12.2023. Verfasst von Seo-Young Lee und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Informatics, College of Medicine, The Catholic University of Korea, Seoul 03083, Republic of Korea. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Mycobacterium bovis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Although the intravesical instillation of Bacillus Calmette-Guerin (BCG) is widely used as adjuvant treatment for nonmuscle-invasive bladder cancers, the clinical benefit is variable across patients, and the molecular mechanisms underlying the sensitivity to BCG administration and disease progression are poorly understood. To establish the molecular signatures that predict the responsiveness and disease progression of bladder cancers treated with BCG, we performed transcriptome sequencing (RNA-seq) for 13 treatment-naïve and 22 post-treatment specimens obtained from 14 bladder cancer patients. To overcome disease heterogeneity, we used non-negative matrix factorization to identify the latent molecular features associated with drug responsiveness and disease progression. At least 12 molecular features were present, among which the immune-related feature was associated with drug responsiveness, indicating that pre-treatment anti-cancer immunity might dictate BCG responsiveness. We also identified disease progression-associated molecular features indicative of elevated cellular proliferation in post-treatment specimens. The progression-associated molecular features were validated in an extended cohort of BCG-treated bladder cancers. Our study advances understanding of the molecular mechanisms of BCG activity in bladder cancers and provides clinically relevant gene markers for evaluating and monitoring patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Informatics, College of Medicine, The Catholic University of Korea, Seoul 03083, Republic of Korea.
- Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul 03083, Republic of Korea.
- Department of Urology, College of Medicine, The Catholic University of Korea, Seoul 03083, Republic of Korea.
- Department of Biomedicine & Health Sciences, Graduate School, The Catholic University of Korea, Seoul 03083, Republic of Korea.
ORCID-Profile: Yun-Hee Lee
Förderung
- National Research Foundation of Korea
Zitieren
APA
Lee, S. Y., Lee, Y. H., Kim, T. M., & Ha, U. S. (2023). Longitudinal Transcription Profiling of Bladder Cancers Dictate the Response to BCG Treatment and Disease Progression. International Journal of Molecular Sciences, 25(1), 144. https://doi.org/10.3390/ijms25010144
Vancouver
Lee SY, Lee YH, Kim TM, Ha US. Longitudinal Transcription Profiling of Bladder Cancers Dictate the Response to BCG Treatment and Disease Progression. International Journal of Molecular Sciences. 2023;25(1):144. doi:10.3390/ijms25010144
BibTeX
@article{Lee2023,
author = {Lee, Seo-Young and Lee, Yun-Hee and Kim, Tae-Min and Ha, U-Syn},
title = {Longitudinal Transcription Profiling of Bladder Cancers Dictate the Response to BCG Treatment and Disease Progression},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {25},
number = {1},
pages = {144},
doi = {10.3390/ijms25010144}
}
EUVIMED